Search clinical trials for: paclitaxel stents

Total 5346 results

Fujian Cancer Hospital

Not yet recruiting

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma | Intermittent Systematic Chemotherapy
Enliven Therapeutics

Recruiting

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Colorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid Tumors

United States
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Asan Medical Center

Not yet recruiting

GIST Oral Paclitaxel(Liporaxel)

Gastrointestinal Stromal Tumors

Korea, Republic of
Ohio State University Comprehensive Cancer Center

Recruiting

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Shanghai Shenqi Medical Technology Co., Ltd

Not yet recruiting

Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications

Portal Hypertension

China
Bio-Thera Solutions

Recruiting

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Endometrial Cancer

China
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Fundación EPIC

Recruiting

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients (PARIS)

Coronary Artery Disease

Spain
GlaxoSmithKline

Recruiting

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)

Carcinoma

Japan
M.D. Anderson Cancer Center

Recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Triple Negative Breast Cancer | Stage 1 cT1b-T1cN0M0

United States
Fudan University

Not yet recruiting

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Pancreatic Cancer
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland, Costa Rica
Zhujiang Hospital

Not yet recruiting

Effectiveness of Atorvastatin in Preventing Cerebrovascular Events After Flow Diverter Implantation

Efficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year | Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year | All-cause Mortality Events (Within 1 Year) | Incident Ischemic Stroke Events (Within 1 Year) | New Hemorrhagic Stroke Events (Within 1 Year) | New... and other conditions
Sinomed Neurovita Technology Inc.

Recruiting

Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms

Intracranial Aneurysm

China
Tongji University

Recruiting

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Esophageal Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Advanced MedTech Solutions Pvt. Ltd.

Not yet recruiting

Advapro Coronary Stent System in Coronary Artery Diseased Patients. (RESTORE)

Coronary Artery Disease | Coronary Stent Implantation | De Novo Stenosis Lesion
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Sun Yat-sen University

Recruiting

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population

Cervical Cancer | Breast Cancer | Non-Small Cell Lung Cancer | Endometrial Cancer | Head And Neck Squamous Cell Carcinomas

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Cervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant Chemoimmunotherapy

China
Rajavithi Hospital

Not yet recruiting

Efficacy of Olanzapine on Weight Gain in Advanced Gynecologic Cancer With Paclitaxel and Carboplatin: a Double Blind, Placebo-controlled Randomized Trial

Weight Gain
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Cervical Cancer | Fertility Preservation | Neoadjuvant Chemoimmunotherapy

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Cervical Cancer | Locally Advanced Cervical Cancer | Concurrent Chemoradiotherapy | Neoadjuvant Chemoimmunotherapy

China
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
Regional Cardiology Center, The Copper Health Centre...
Department of Cardiology, Provincial Specialized Hospital in Legnica, 59-200...

Recruiting

Lower Silesia Culotte Bifurcation Registry (LSCBR). (LSCBR)

Safety Issues | Efficacy, Self

Poland
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
China National Center for Cardiovascular Diseases

Not yet recruiting

CT-derived Virtual Stenting Optimize Coronary Revascularization (CT-COMPASS) (CT-COMPASS)

Percutaneous Coronary Intervention | Computed Tomography | Coronary Physiology

China
National Institute of Cardiology, Warsaw, Poland

Not yet recruiting

Drug-Coated Balloon in Native Chronic Total Occlusion Percutaneous Coronary Intervention (IMAGINATION)

Coronary Artery Disease | Total Occlusion of Coronary Artery

Poland
Concept Medical Inc.
Cardiovascular Research Foundation, New York

Not yet recruiting

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels (MAGICAL-SV)

Cardiovascular Diseases | Coronary Artery Disease | Native Coronary Artery Stenosis
Eve Rodler

Not yet recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Breast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditions

United States
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)

China
Lai-ping Zhong
Sun Yat-sen University; Fudan University; Fujian Medical University; Central South...

Recruiting

Neoadjuvant Immunochemotherapy for LAOSCC

Oral Squamous Cell Carcinoma | Locally Advanced Head and Neck Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer (PTCA199-11)

Pancreatic Adenocarcinoma

China
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Uroial Plus in the Management of Infections and Urinary Symptoms Associated With Ureteral Stents (USSIAL)

Urinary Tract Infections | Ureteral Stent-Related Symptom
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)

Triple Negative Breast Cancer

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Cervical Carcinoma

China
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

China
Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China

Search clinical trials for: paclitaxel stents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations